

Prioritizing Heart Transplantation During the COVID-19 Pandemic

Keki Balsara¹, Zakiur Rahaman¹, Emily Sandhaus¹, Jordan Hoffman¹, Sandip Zalawadiya¹, William McMaster¹, JoAnn Lindenfeld¹, Mark Wigger¹, Tarek Absi¹, Douglas Brinkley¹, Jonathan Menachem¹, Lynn Punnoose¹, Suzie Sacks¹, Kelly Schlendorf¹, and Ashish Shah¹

¹Vanderbilt University Medical Center

January 29, 2021

Abstract

BACKGROUND: COVID-19 has significantly impacted the healthcare landscape in the United States in a variety of ways including a nation-wide reduction in operative volume. The impact of COVID-19 on the availability of donor organs and the impact on solid organ transplant remains unclear. We examine the impact of COVID-19 on a single, large-volume heart transplant program. **METHODS:** A retrospective chart review was performed examining all adult heart transplants performed at a single institution between March 2020 and June 2020. This was compared to the same time frame in 2019. We examined incidence of primary graft dysfunction (PGD), continuous renal replacement therapy (CRRT) and 30-day survival. **RESULTS:** From March-June 2020, 43 orthotopic heart transplants were performed compared to 31 performed during 2019. Donor and recipient demographics demonstrated no differences. There was no difference in 30-day survival. There was a statistically significant difference in incidence of post-operative CRRT (9/31 v. 3/43; $p = .01$). There was a statistically significant difference in race (23W/8B/1AA v. 30W/13B; $P=.029$). **CONCLUSION:** We demonstrate that a single, large-volume transplant program was able to grow volume with little difference in donor variables and clinical outcomes following transplant. While multiple reasons are possible, most likely the reduction of volume at other programs allowed us to utilize organs to which we would not have previously had access. More significantly, our growth in volume was coupled with no instances of COVID-19 infection or transmission amongst patients or staff due to an aggressive testing and surveillance program.

Prioritizing Heart Transplantation During the COVID-19 Pandemic

Keki R. Balsara MD MBA¹, Zakiur Rahaman MD¹, Emily Sandhaus BSN², Jordan Hoffman MD¹, Sandip Zalawadiya MD², William McMaster Jr MD¹, Joann Lindenfeld MD², Mark Wigger MD², Tarek Absi MD¹, Douglas M. Brinkley MD², Jonathan Menachem MD², Lynn Punnoose MD², Suzie Sacks MD², Kelly Schlendorf MD MSCI², Ashish S. Shah MD¹

¹ *Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN 37232*

² *Department of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN 37232*

Word Count: 2212 Manuscript; 245 Abstract

Key Words: Heart transplantation; COVID-19; resource allocation

Running Title: Heart Transplantation in the COVID-19 Era

Corresponding Author:

Keki R. Balsara, MD, MBA

Vanderbilt University Medical Center

Nashville, TN 37232

Keki.r.balsara@vumc.org

ABSTRACT:

BACKGROUND:

COVID-19 has significantly impacted the healthcare landscape in the United States in a variety of ways including a nation-wide reduction in operative volume. The impact of COVID-19 on the availability of donor organs and the impact on solid organ transplant remains unclear. We examine the impact of COVID-19 on a single, large-volume heart transplant program.

METHODS:

A retrospective chart review was performed examining all adult heart transplants performed at a single institution between March 2020 and June 2020. This was compared to the same time frame in 2019. We examined incidence of primary graft dysfunction (PGD), continuous renal replacement therapy (CRRT) and 30-day survival.

RESULTS:

From March-June 2020, 43 orthotopic heart transplants were performed compared to 31 performed during 2019. Donor and recipient demographics demonstrated no differences. There was no difference in 30-day survival. There was a statistically significant difference in incidence of post-operative CRRT (9/31 v. 3/43; $p = .01$). There was a statistically significant difference in race (23W/8B/1AA v. 30W/13B; $P=.029$).

CONCLUSION:

We demonstrate that a single, large-volume transplant program was able to grow volume with little difference in donor variables and clinical outcomes following transplant. While multiple reasons are possible, most likely the reduction of volume at other programs allowed us to utilize organs to which we would not have previously had access. More significantly, our growth in volume was coupled with no instances of COVID-19 infection or transmission amongst patients or staff due to an aggressive testing and surveillance program.

INTRODUCTION:

Heart transplantation remains the definitive therapy for patients who suffer from end-stage heart failure. Since it was first performed in 1967, the number of patients who have benefited from this therapy has continued to increase^{1,2}. The past two decades have seen the introduction of new, improved immunosuppression which has allowed for longer allograft survival and innovations in donor recovery. The organ donor pool has been expanded by the utilization of hepatitis C donors and ex vivo perfusion platforms³. These developments hold promise for the meaningful increase in the number of adult heart transplants performed in the United States.

The spring of 2020 saw the widespread recognition of a novel coronavirus (COVID-19) which has had a global impact. In the United States, the affect has been wide ranging. Nowhere has this been more apparent than the healthcare landscape. An increase in demand for hospital beds for COVID-19 positive patients coupled with hospital-driven initiatives to reduce non-emergent treatments has resulted in a nation-wide reduction in operative volume⁴. Moreover, patient concerns regarding infection with COVID-19 has resulted in many patients deferring medical care for both major and minor concerns⁵. At its worst, we witnessed reduction in case volume between 20-90% compared to last year across all service lines at our hospital.

The impact of COVID-19 on the availability of donor organs and the impact on solid organ transplant remains unclear. Here we examine the impact of COVID-19 on a single, large-volume heart transplant program.

METHODS:

Institutional Review Board approval at the Vanderbilt University Medical Center was obtained. We performed a retrospective chart review examining all adult heart transplants performed between March 2020 and June 2020. This was compared to the same time frame in 2019. We examined demographic data and outcomes which included incidence of primary graft dysfunction (PGD), continuous renal replacement therapy (CRRT), length of stay and 30-day survival. In addition, donor variables including hepatitis C status and distance from our transplant center were examined. Statistical analysis was performed with Microsoft Excel (Redmond, Washington).

RESULTS:

The first confirmed case of COVID-19 in the state of Tennessee was on March 5, 2020. By June 30, 2020, the total number of confirmed cases in the state was 43,806. Over this same period of time, our total cardiac volume was 488 cases compare to 521 cases during March-June 2019. The most significant decrease in volume was seen in April 2020 where volume was reduced by nearly 30% compared to the previous year.

From March-June 2020, 43 total orthotopic heart transplants were performed. This includes three re-transplants and seven multi-organ transplants (6 heart/kidney; 1 heart/liver; 0 heart/lung). The average recipient age was 54.2 +/- 13.9 years and 29 recipients were male and 14 were female. Thirty recipients were Caucasian. Thirteen recipients were African American. There were 11 blood type A recipients, seven blood type B recipients, one blood type AB recipient and 24 blood type O recipients. Sixteen patients had pre-operative durable left ventricular assist devices (LVAD). The average listing status at time of transplant was 3.3 +/- 1.4. The average time on the wait list was 147.44 +/- 195.85 days.

From March-June 2019, 31 total orthotopic heart transplants were performed. This includes three re-transplants and three multi-organ transplants (3 heart/kidney; 0 heart/liver; 0 heart/lung). The average recipient age was 47.5 +/- 13.3 years and 18 recipients were male and 13 were female. Twenty-three patients were Caucasian. Eight patients were African American. One patient was Asian-American. There were 15 blood type A recipients, five blood type B recipients, one blood type AB recipient and 10 blood type O recipients. Eight patients had pre-operative durable left ventricular assist devices (LVAD). The average listing status at time of transplant was 3.0 +/- .99. The average time on the wait list was 112.94 +/- 260.11 days. There was no significant difference in recipient demographic variables across groups except for race of the transplant recipients ($p= 0.029$) (TABLE 1).

Donor variables over these two time periods were not different (TABLE 2). From March-June 2020, the average donor age was 29.1 +/- 8.3 years and 30 donors were male and 13 were female. Thirty-one donors were Caucasian. Seven donors were African American. One donor was Hispanic. One donor was Native American. Ten donors were hepatitis C positive. Twenty donors were characterized as high risk. The average time of allograft travel to the recipient hospital was 88.49 +/- 53.5 minutes.

From March-June 2019, the average donor age was 32.0 +/- 8.8 years and 18 donors were male and 13 were female. Twenty-six donors were Caucasian. Three donors were African American. Two donors were Hispanic. Fifteen donors were hepatitis C positive. Seventeen donors were characterized as high risk. The average time of allograft travel to the recipient hospital was 87.87 +/- 36.05 minutes. In addition, there was no difference in the number of local versus imported organs over these two periods of time.

Of the 43 transplants performed between March-June 2020, 41 achieved 30-day survival. Four recipients needed post-operative continuous renal replacement therapy. The average total length of stay was 18.2 +/- 8.1 days and the average intensive care unit length of stay was 6.1 +/- 3.1 days. Four patients had primary graft dysfunction and six patients had rejection (2R or greater) at 30 days⁶.

Of the 31 transplants performed between March-June 2019, 30 achieved 30-day survival. Nine patients needed post-operative continuous renal replacement therapy. The average total length of stay was 23.0 +/- 13.4 days and the average intensive care unit length of stay was 11.0 +/- 8.7 days. Three patients had primary graft dysfunction and three patients had rejection (2R or greater) at 30 days. The only significant difference in recipient outcome was the incidence of continuous renal replacement therapy ($p= 0.01$) (Table

3).

There was no evidence of acute, post-operative infection of any recipient with COVID-19 during this time period.

DISCUSSION:

Heart transplantation remains the definitive therapy for patients with end stage heart disease. The number of heart transplants performed in the United States has gradually increased to approximately 3000/year over the past 20 years⁷. The recent past has seen the introduction of a variety of means by which the donor pool may increase including ex vivo support platforms, older donors and extended criteria donors.

However, much of the potential benefit of these advances have not been recognized in the past year due to a world-wide pandemic secondary to COVID-19. In the United States, more than nine-million individuals have been infected and nearly 250,000 individuals have died as a result of infection⁸. The impact of this pandemic on the healthcare landscape has yet to be fully realized but it is likely to be substantial. The late spring and early summer saw widespread mitigation attempts including the shuttering of schools, places of work and businesses. Initial uncertainty regarding the scale of infection, the need for healthcare resources and the availability of personal protective equipment prompted many centers to institute moratoriums on all non-emergent care⁹. Anecdotal evidence suggests that many individuals did not seek medical care for non-COVID related chronic illness and more still did not present for urgent/emergent care.

The impact of COVID-19 on solid organ transplant, particularly orthotopic heart transplant, remains unclear. Scientific Registry of Transplant Recipients (SRTR) data suggests that many programs in geographically hard-hit areas significantly reduced or stopped all solid organ transplants¹⁰. The driver behind these observations has yet to be fully elucidated. As one of the largest heart transplant programs in the country, we were able to navigate the pandemic while keeping our program open.

At the height of the COVID lockdown between March and June 2020, we were able to increase our transplant volume by nearly 40%. Our ability to do this is attributable to both nation-wide trends regarding transplant during this time as well as institutional initiatives which prioritized the maintenance of programs which offered life-saving therapies. An examination of our program's performance during this time highlights many of the tensions that predated COVID-19 for transplant programs nationwide and perhaps provides a model for how to expand orthotopic heart transplant availability in the post-COVID era.

As we look at demographic information for donors and recipients, a few interesting observations were made. There was no significant difference in age of donor or recipient, no significant difference in status at the time of transplant and no significant difference in travel time of the allograft to our center. There was, however, a statistically significant difference in race of recipients between the two time periods, with the COVID era having a greater number of recipients of color. The specific reason for this remains unclear. Many studies demonstrate that people of color have a reduced incidence of transplant and have more complications compared to Caucasian recipients¹¹. Access to care, comorbidities and financial limitations have all been identified as potential reasons. Our program has made a concerted effort to identify potentially reversible barriers to transplant and address them in a multidisciplinary fashion such that certain socio-economic limitations do not prevent patients from transplant. It is a testament to the success of these endeavors that during a pandemic which disproportionately affected people of color, these patients' access to life-saving heart transplant was not impacted.

Outcomes including 30-day survival, length of stay, primary graft dysfunction and rejection were unchanged. There was a significant decrease in the incidence of post-operative renal replacement therapy in those patients who underwent transplant during the COVID era. This, most likely, had less to do with COVID and more to do with some changes to our intra- and post-operative management of these patients. We have seen an overall trend towards less utilization of renal replacement therapy in our post-transplant patients.

More significant, perhaps, is the focus our institution placed on maintaining and even expanding access to transplant during this time. We speculate that while many programs curtailed transplant activity due to

capacity constraints secondary to COVID hospitalization and personal protective equipment conservation efforts, our institution elected to prioritize the maintenance of our transplant programs. The end result, potentially, was that we had access to organs that, under normal circumstances, would have been utilized by surrounding programs.

From an institutional perspective, we implemented a rigorous program of testing, monitoring and isolating pre- and post-transplant patients from the remainder of patients in the hospital. This included testing on admission and immediately prior to transplant, co-localizing transplant patients in a single intensive care unit and a single step-down unit and the most rigorous utilization of personal protective equipment in all interactions with transplant patients. The end result was that at no point during this study period was a patient or staff member taking care of these patients noted to develop COVID-19. In addition, travel restrictions and limited access to donor hospitals forced us to rethink procurement strategies. We relied much more heavily on local surgeons to recover organs for us, a shift from traditional practice. These initiatives could very well represent a paradigm shift in the manner in which organs are procured, eliminating certain personnel constraints that are common in a program of our size.

As an institution, we were not immune to the impact of COVID-19. Like many institutions across the country, we scaled back “elective” procedures to ensure enough resources for urgent/emergent care. This naturally raised a number of questions surrounding which services would be offered and what would be considered urgent/emergent. The same ethical principles inherent to transplant practices continue to apply during the COVID-19 era, but the balance between autonomy, beneficence, nonmaleficence, and justice will be inherently fluid. Transplantation is inherently a resource intensive service. Recipients demand close monitoring by staff, long stays in an intensive care unit, utilization of ventilators and blood products, and use of personal protective equipment. Additionally, immunosuppressed individuals are at higher risk of being susceptible to a highly infectious, aerosolized virus. Moreover, staff safety concerns regarding travel on planes and prolonged periods of time in the operating room or ward must be considered. Perhaps most importantly is the acknowledgement that transplantation is never an elective procedure. Patients awaiting heart transplant often have no alternative therapy that can provide long-lasting results. While inotropic therapy and ventricular assist device support are options for some, they do not provide the durable results found with transplant. Without knowing when this pandemic will end, is it fair to deprive patients of potentially more life-extending therapy? Another consideration is the fact that donor organs are not widely available. For some patients who have waited months or years on a waitlist, should they be deprived of transplant when a suitable donor is identified? While there are no clear answers to these ethical considerations, we sought to find a delicate balance between access to care for the many as a result of the pandemic and specialized care for the few in need of a life-saving transplant.

In the final analysis, COVID-19 has dramatically affected all aspects of our lives. Perhaps nowhere has this been more readily apparent than in the healthcare space. In spite of that impact, we demonstrate that orthotopic heart transplants can continue to be performed safely. While we cannot deny that we potentially benefited from other programs’ reduction in volume, what we have truly demonstrated is that a rigorous testing and surveillance program allows one to continue providing this life-saving therapy, while ensuring the health and safety of both patients and providers.

TABLE 1: Heart transplant recipient demographics for 2019 and 2020. There was a statistically significant difference in race of recipients between the two groups ($p= 0.029$). **Gender:** M = male; F = female. **Race:** C = Caucasian; AA = African American; A = Asian American.

	March 2019 – June 2019	March 2020 – June 2020
Number of Recipients	31	43
Age (years)	47.5+/-13.1	54.2+/-13.9
Gender	18M/13F	29M/14F
Pre-op VAD	8	16
Re-transplant	3	3

	March 2019 – June 2019	March 2020 – June 2020
Race	23C/8AA/1A	30C/13AA
Blood Type	15A/5B/1AB/10O	11A/7B/1AB/24O
Status at listing	3.0+/-0.99	3.3+/-1.4
Time on waitlist (days)	112.94+/-260.11	147.44+/-195.85

TABLE 2: Heart transplant donor demographics for 2019 and 2020. There were no statistically significant differences. **Gender:** M = male; F = female. **Race:** C = Caucasian; AA = African American; A = Asian American; H = Hispanic; NA = Native American.

	March 2019 – June 2019	March 2020 – June 2020
Age (years)	32.0+/-8.8	29.1+/-8.3
Gender	18M/13F	30M/13F
Race	26C/3AA/2H	31C/7AA/1H/1NA
HCV+	15	10
Travel Time (minutes)	87.81+/-36.05	88.49+/-53.5

TABLE 3: Heart transplant outcomes for 2019 and 2020. There was a statistically significant difference in the incidence of continuous renal replacement therapy (CRRT) between the two groups ($p= 0.01$). **LOS** = length of stay. **PGD** = primary graft dysfunction. Rejection at 30 days was defined as 2R or greater at biopsy.

	March 2019 – June 2019	March 2020 – June 2020
30 day survival	30	41
LOS (ICU) (days)	23.0+/-13.4	18.2+/-8.1
LOS (Total) (days)	11.0+/-8.7	6.1+/-3.1
PGD	3	4
Rejection at 30 days	3	6
CRRT post-op	9	4

REFERENCES:

1. Barnard CN. The operation: A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *South African Medical Journal*; December 30, 1967; 41(48): 1271-1274.
2. Holm AM, Mehra M, Courtwright A, et al. Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. *The Journal of Heart and Lung Transplantation*; July 2020; 39(7):619-626.
3. Schelndorf KH, Zalawadiya S, Shah AS, et al. Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C. *JAMA Cardiology*; February 2020; 8(2):87-99.
4. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of COVID-19. *New England Journal of Medicine*; May 21, 2020; 382:2049-2055.
5. American College of Surgeons, American Society of Anesthesiologists, Association of perioperative Registered Nurses, American Hospital Association. Joint statement: roadmap for resuming elective surgery after COVID 19 pandemic. April 17, 2020.
6. Jeessup M, Drazner MH, Book W, et al. 2017 ACC/AGA/HFSA/ISHLT/ACP advanced training statement on advanced heart failure and transplant cardiology (revision of the

- ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced hear failure and cardiac transplant): A report of the ACC competency management committee. *Circulation: Heart Failure*; June 2017; 10(6).
7. Goff RR, Uccellini K, Lindblad K, et al. A change of heart: preliminary results of the US 2018 adult heart allocation revision. *American Journal of Transplantation*; October 2020; 20(10): 2781-2790.
 8. World Health Organization 2020 coronavirus disease (COVID-19) pandemic. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
 9. White DB, Lo B. A framework for rationing of ventilators and critical care beds during COVID-19 pandemic. *JAMA*; May 12, 2020; 323(18):1773-1174.
 10. Scientific Registry of Transplant Recipients. Available at <https://www.srtr.org>.
 11. Cox K, Carter K, Lirette S, et al. Donor and recipient racial mismatch impacts thoracic organ transplant survival. *The Journal of Heart and Lung Transplantation*; April 2019; 38(4): S266-S267.